Age and the neuromuscular blockading effects of cisatracurium.

PURPOSE To investigate the influence of age on the neuromuscular blocking effect of cisatracurium. METHODS 90 patients with ASA I and II were assigned to the following groups according to their age: adults, children, and infants. Each group was subdivided into three subgroups according to the first dose of cisatracurium. Patients were administrated at a first dose of cisatracurium randomly, and their responses to train-of-four (TOF) stimulation were observed. When the same degree of the first response (T1) continuously repeats three times, the percentage of T1 inhibition was recorded, and the curve of dose-effect relationship and ED95 were calculated. A second dose of cisatracurium was then administrated (total volume 100 μg/kg). The recovery phase in each patient was observed upon T1 reaching the maximum blocking effect (100%). RESULTS Once the maximum blocking effect was reached, patients were intubated. There were 83 cases (92.2%) of patients with grade 1 and 7 (7.8%) patients with grade 2 intubating conditions. ED95 was 59.29, 55.88 and 45.39 μg/kg in adults, children, and infants, respectively. ED95 positively correlated with age. The clinical duration of neuromuscular blockade, effective action duration of neuromuscular blockade, and in vivo action duration of neuromuscular blockade in adults was longer than that in children (P<0.05), but shorter than in infants (P<0.05). However, there were no significant differences in the recovery index among groups (P>0.05). CONCLUSION Age influences the neuromuscular blocking effects of cisatracurium to a certain extent.

[1]  Jieying Gao,et al.  High-performance liquid chromatography assay with programmed flow elution for cisatracurium in human plasma: application to pharmacokinetics in infants and children. , 2014, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[2]  H. Sharifnia,et al.  Cost analysis and safety comparison of Cisatracurium and Atracurium in patients undergoing general anesthesia. , 2013, European review for medical and pharmacological sciences.

[3]  K. Lim,et al.  The effect of low dose ketamine and priming of cisatracurium on the intubating condition and onset time of cisatracurium , 2012, Korean journal of anesthesiology.

[4]  F. Varin,et al.  Cisatracurium pharmacokinetics and pharmacodynamics during hypothermic cardiopulmonary bypass in infants and children , 2011, Paediatric anaesthesia.

[5]  李军,et al.  The neuromuscular blocking effect of different doses of cisatracurium in children , 2007 .

[6]  Hu Aiping,et al.  Pharmacodynamics of Cisastracurium in Children at Different Age , 2007 .

[7]  C. Launo,et al.  Cisatracurium versus vecuronium: a comparative, double blind, randomized, multicenter study in adult patients under propofol/fentanyl/N2O anesthesia. , 2006, Minerva anestesiologica.

[8]  U. Aypar,et al.  Infusion and bolus administration of cisatracurium--effects on histamine release. , 2005, Middle East journal of anaesthesiology.

[9]  T. Riedel,et al.  [Cis-atracurium--an equivalent substitution for atracurium in pediatric anesthesia?]. , 2002, Anaesthesiologie und Reanimation.

[10]  M. Crawford,et al.  Dose–Response Relationship and Infusion Requirement of Cisatracurium Besylate in Infants and Children during Nitrous Oxide–Narcotic Anesthesia , 2001, Anesthesiology.

[11]  F. Xue,et al.  [Influences of age and gender on dose-response and recovery time-course of atracurium]. , 2001, Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae.

[12]  H. Yannan.  Histamine release and hemodynamic changes caused by cisatracurium , 2001 .

[13]  G. Bikhazi,et al.  Pharmacodynamics and intubating conditions of cisatracurium in children during halothane and opioid anesthesia. , 2000, Journal of clinical anesthesia.

[14]  S. Tibby,et al.  Clinical validation of cardiac output measurements using femoral artery thermodilution with direct Fick in ventilated children and infants , 1997, Intensive Care Medicine.

[15]  T. Taivainen,et al.  Pharmacokinetics and pharmacokinetic-dynamic modelling of rocuronium in infants and children. , 1997, British journal of anaesthesia.

[16]  C. Lien,et al.  Importance of the Organ-Independent Elimination of Cisatracurium , 1996, Anesthesia and analgesia.

[17]  L. Skovgaard,et al.  Good Clinical Research Practice (GCRP) in pharmacodynamic studies of neuromuscular blocking agents , 1996, Acta anaesthesiologica Scandinavica.

[18]  R. Welch,et al.  The in vitro degradation of cisatracurium, the R, cis‐R′‐isomer of atracurium, in human and rat plasma , 1995, Clinical pharmacology and therapeutics.

[19]  C. Lien,et al.  The Cardiovascular Effects and Histamine‐releasing Properties of 51W89 in Patients Receiving Nitrous Oxide/Opioid/Barbiturate Anesthesia , 1995, Anesthesiology.

[20]  T. Taivainen,et al.  Pharmacodynamic effects of 51W89, an isomer of atracurium, in children during halothane anaesthesia. , 1995, British journal of anaesthesia.

[21]  O. Meretoja,et al.  Duration of action of vecuronium in infants and children anaesthetized without potent inhalation agents , 1989, Acta anaesthesiologica Scandinavica.